J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Jafron Biomedical Co Ltd
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Accrued Liabilities
ÂĄ116.9m
CAGR 3-Years
14%
CAGR 5-Years
20%
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Accrued Liabilities
ÂĄ132.8m
CAGR 3-Years
41%
CAGR 5-Years
42%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Accrued Liabilities
ÂĄ321.1m
CAGR 3-Years
38%
CAGR 5-Years
42%
CAGR 10-Years
49%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Accrued Liabilities
ÂĄ3.9B
CAGR 3-Years
15%
CAGR 5-Years
25%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Accrued Liabilities
ÂĄ133.1m
CAGR 3-Years
26%
CAGR 5-Years
3%
CAGR 10-Years
26%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Accrued Liabilities
ÂĄ879.6m
CAGR 3-Years
14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
46.98 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Accrued Liabilities?
Accrued Liabilities
116.9m CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Accrued Liabilities amounts to 116.9m CNY.

What is Jafron Biomedical Co Ltd's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
20%

Over the last year, the Accrued Liabilities growth was -5%. The average annual Accrued Liabilities growth rates for Jafron Biomedical Co Ltd have been 14% over the past three years , 20% over the past five years .

Back to Top